<i>RAB18</i> regulates extrahepatic siRNA-mediated gene silencing efficacy.

ABSTRACT: Small interfering RNAs (siRNAs) hold considerable therapeutic potential to selectively silence previously "undruggable" disease-associated targets, offering new opportunities to fight human diseases. This therapeutic strategy, however, is limited by the inability of naked siRNAs to passively diffuse across cellular membranes due to their large molecular size and negative charge. Delivery of siRNAs to liver through conjugation of siRNA to N-acetylgalactosamine (GalNAc) has been a success, providing robust and durable gene knockdown, specifically in hepatocytes. However, the poor delivery and silencing efficacy of siRNAs in other cell types has hindered their applications outside the liver. We previously reported that a genome-wide pooled knockout screen identified RAB18 as a major mo

SUBMITTER: Lu J 

PROVIDER: S-EPMC11458997 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature